MeSH D018357 - respiratory syncytial virus infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ribavirin | Ribavirin |  | 2004-10-04 |  |  |
| Ribavirin | Ribavirin Teva |  | 2009-03-31 |  |  | |
| Ribavirin | Ribavirin Teva Pharma B.V |  | 2009-07-01 |  |  | |
| Mylan | Ribavirin | Ribavirin Mylan (previously Ribavirin Three Rivers) |  | 2010-06-10 |  |  |
| Roche | Ribavirin | Copegus |  | 2002-12-03 |  |  |
| Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  | |
| Sandoz | Ribavirin | Ribavirin |  | 2006-10-03 |  |  |
| AstraZeneca | Palivizumab | Synagis |  | 1999-08-13 | $215 M | Q1/21-Q2/23 |
| Bausch Health Companies | Ribavirin | Virazole |  | 1985-12-31 |  |  |
| Merck Sharp & Dohme | Ribavirin | Cotronak |  | 1999-05-07 |  |  |
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack |  | 2008-06-13 |  |  | |
| Ribavirin | Rebetol |  | 1998-06-03 |  |  | |
| Aurobindo Pharma | Ribavirin | Ribavirin |  | 2009-09-17 |  |  |
| Zydus Therapeutics | Ribavirin | Ribavirin |  | 2005-12-05 |  |  |
| Chartwell Pharmaceuticals | Ribavirin | Ribasphere |  | 2004-04-06 |  |  |
| Ribavirin | Ribavirin |  | 2004-04-06 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
44%4/9
Phase 2
83%5/6
Phase 3
63%5/8
Approved: 3Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use